Among the First at Lurie Children’s: Emmanuel’s Path to a Cure for Sickle Cell Disease

Emmanuel vividly remembers when pain crises started to disrupt his life. 

“I was in first-grade gym class, and I just remember being in horrible knots of pain, screaming and crying,” he said. “The school nurses didn’t know how to handle my situation. I was rushed to the hospital and stayed for a few days.”

Devastating, disruptive pain crises are a common symptom of sickle cell disease, the inherited blood disorder that Emmanuel was born with. The condition, which affects roughly 100,000 Americans, can cause life-threatening complications and organ damage. Most people with untreated sickle cell disease die at a median age of 40 to 45 years old.

Throughout Emmanuel’s childhood and adolescence, hospitalizations, missed school days and physical limitations became a regular part of life. Temporary treatments helped manage pain, but nothing stopped the cycle. Sports fell out of reach. Cold weather, summer heat and even social events required careful planning.

A historically underfunded and under-researched condition, sickle cell disease saw slow treatment progress for decades. Most care focused on managing pain and preventing complications rather than offering a path to cure.

“The lack of solutions hindered me from doing sports,” he said. “I always dreamed of doing track but was not physically capable.” Instead, Emmanuel poured himself into writing and performing music as a way to channel feelings of isolation and hopelessness.

“I was just assuming I was on borrowed time,” he said, “and at any time, a pain crisis could take me out.” 

Emmanuel’s parents Lucy and Elias saw “the light in him was being dimmed,” they said. That’s when they decided to take him to Ann & Robert H. Lurie Children’s Hospital of Chicago for a second opinion.

Curiosity Leads to a Cure 

For Emmanuel, new possibilities appeared once he met his care team led by Dr. Robert Liem, Division Head of Hematology, Oncology, Neuro-Oncology and Stem Cell Transplantation and Dr. Sonali Chaudhury, Section Head of Stem Cell Transplantation and Cellular Therapies at Lurie Children’s.

At age 20, Emmanuel began volunteering for clinical trials. “If there’s a way for me to test out something meant to help me feel better or help others, why not?” he said.

That curiosity positioned Emmanuel for something far bigger than he imagined. His care team introduced him to a novel gene therapy option being studied through a landmark, National Institutes of Health (NIH)-led clinical trial. Lurie Children’s was one of a select group of pediatric hospitals in the U.S. invited to participate, giving patients like Emmanuel access to research that is actively reshaping possibilities for sickle cell disease.

“For the first time, my team looked me in the eye and said, ‘We think we can cure this,’ Emmanuel said.  

The NIH trial not only tests the treatment, but helps to establish the future standard of care for children and young adults with sickle cell disease by refining safer, more effective delivery methods for gene therapy.

Gene therapy offers a world of possibility for patients who historically had none. For decades, the only curative option for sickle cell disease was a stem cell transplant from a matched sibling donor, an option unavailable to nearly 80 percent of patients, including Emmanuel.

Through this NIH-supported research, Emmanuel was one of the first patients at Lurie Children’s to receive a therapy designed using his own genetically modified stem cells, eliminating the need for a donor match.

Emmanuel embarked on the year-long process for the treatment that ultimately proved successful. More than a year later, he has lived completely symptom-free – something he and his family once could only dream of.  

After witnessing Emmanuel’s life-changing success, his little sister, Hannah, plans to undergo the same treatment at Lurie Children’s. “Seeing Emmanuel go without a crisis, without a hospitalization, I have a lot of hope for my daughter as well,” Lucy said. 

“For the first time in my life, I feel like I have a future,” Emmanuel said. “I’m living proof of the advancements in care being made for children with genetic conditions,” Emmanuel said.